Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Despite some market exclusivity concerns, GERN still has many years of sales ahead, unencumbered by generic competition.
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs
Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Cytek Biosciences (CTKB) to $5.25 from $4.50 and keeps a Sell rating on ...
3 Big Red Flags That Could Trigger a CRA Audit on Your TFSA
TFSA users engaging in business-like activities for profit will trigger a CRA audit. The post 3 Big Red Flags That Could Trigger a CRA Audit on Your TFSA appeared first on The Motley Fool Canada.
Worth the Hype: Palantir’s Ontology, Switching Costs Warrant Quadrupling of Our Fair Value Estimate
We view Palantir’s financial position as healthy and improving. As of September, Palantir had nearly $800 million in cash and $3.8 billion in marketable securities (mostly US Treasury securities) and ...